Review Article

Orodispersible Delivery Systems for Verapamil Hydrochloride

Jyoti*, Satinder Kakar

Himachal Institute of Pharmacy, Poanta Sahib, Himachal Pradesh, India

Received: 31-12-2025 / Revised: 27-12-2025 / Accepted: 18-02-2026

Abstract

Verapamil Hydrochloride, a Class IV calcium channel antagonist, is a primary intervention for hypertension and arrhythmias. However, its clinical efficacy is restricted by a significant first-pass effect, yielding only 10%-20% systemic bioavailability. To overcome these pharmacokinetic barriers and address patient non-compliance due to dysphagia, Orodispersible Tablets (ODTs) have been developed as a high-performance alternative. This review explores the engineering of ODTs designed to liquefy instantly in the oral cavity. Success depends on the strategic use of superdisintegrants like Crospovidone and sublimation agents (e.g., camphor) to create a highly porous internal architecture. These methods facilitate rapid wicking and capillary action, often ensuring disintegration in under 30 seconds. Beyond convenience, the ODT platform offers a potential "shunt" for drug molecules to be absorbed via the pregastric mucosa, partially bypassing hepatic degradation.

Current research highlights the move toward natural polymers and factorial design optimization to balance mechanical durability with rapid dissolution. By masking the drug's inherent bitterness through ion-exchange resins or complexation, ODTs provide a seamless, water-free delivery system. This technology represents a vital advancement in cardiovascular pharmacotherapy, ensuring rapid onset and enhanced patient-centric care.

Keywords: Verapamil, Orodispersible Tablet, Antihypertensive

Introduction

In the realm of cardiovascular medicine, the management of conditions such as supraventricular arrhythmias and chronic hypertension has historically been anchored by Verapamil Hydrochloride (VHCl). This agent, a primary member of the phenylalkylamine class of calcium channel blockers, achieves its therapeutic effect through the selective blockade of L-type voltage-sensitive calcium channels located in the vascular smooth muscle and myocardial tissues [1-3].However, the clinical utility of VHCl is significantly constrained by its pharmacokinetic limitations. Although the drug undergoes nearly total absorption within the gastrointestinal tract, its systemic bioavailability is marginalized to a range of 10%–22% due to rigorous presystemic hepatic metabolism [4]This metabolic barrier necessitates frequent or high-dose administration, which can exacerbate adverse effects.



To overcome these physiological hurdles and align with the modern "patient-centric" pharmaceutical model, research has pivoted toward Orodispersible Tablets (ODTs). Recognized by major pharmacopoeias (USP and BP) as dosage forms that fragment in the mouth—usually in less than half a minute—without requiring fluid intake, ODTs represent a significant evolution in oral delivery. This platform is especially vital for the approximately 30% of elderly patients and many pediatric groups suffering from dysphagia, for whom conventional tablets often lead to poor treatment adherence. Crucially, the ODT format facilitates transmucosal absorption through the sublingual and buccal membranes, creating a "mucosal shunt" that bypasses the portal circulation and potentially improves the drug's therapeutic index [1-3]. Engineering a robust VHCl-ODT involves a technical equilibrium between structural integrity, palatability, and nearly instantaneous disintegration. At the core of this technology are superdisintegrants, which promote matrix breakdown via capillary wicking, rapid swelling, and deformation recovery [4-7]. Scientific literature has extensively documented the use of both synthetic polymers, such as Crospovidone and Croscarmellose Sodium, and

*Correspondence
Jyoti
Himachal Institute of Pharmacy,Paonta Sahib,H.P,India

novel natural mucilages to minimize wetting periods and maximize water affinity. Furthermore, since VHCl possesses a naturally acrid taste, the integration of masking technologies—such as beta-cyclodextrin inclusion complexes and ion-exchange resins—is mandatory to ensure patient acceptance.

Contemporary manufacturing has advanced beyond basic direct compression to include high-porosity techniques like sublimation, microwave-assisted drying, and additive manufacturing (3D printing). Innovative methods such as lyophilization and solid foam technology are also employed to generate "honeycomb" matrices that facilitate immediate liquid ingress. This review provides a comprehensive analysis of these formulation advancements, detailing the synergy between functional excipients and optimized processing parameters in the development of high-bioavailability Verapamil interventions [8-10]

Formulation Components and Functional Excipients

The architecture of a Verapamil Hydrochloride (VHCl) ODT is a delicate synergy of materials designed to promote rapid hydraulic failure of the tablet matrix.

The Kinetic Role of Superdisintegrants

The primary drivers of ODT performance are superdisintegrants, which are integrated at optimized concentrations to ensure the tablet transitions from a solid to a fine suspension within seconds.

Wicking and Porosity: Agents like Crospovidone function via capillary action, pulling saliva into the internal "honeycomb" structure without forming a viscous gel that might impede further liquid ingress.

- Hydration Swelling: Croscarmellose Sodium and Sodium Starch Glycolate exhibit significant volumetric expansion upon contact with moisture, exerting internal pressure that shatters the tablet binder.
- Natural Alternatives: Recent research by Patil & Joshi and Kumar & Gupta has highlighted the efficacy of plant-derived mucilages, which offer comparable disintegration profiles with enhanced biocompatibility.

Organoleptic Optimization: Taste Masking

Because VHCl is inherently acrid, palatability is a critical barrier to patient adherence. Advanced molecular interventions are utilized to prevent the drug from interacting with lingual gustatory receptors.

- Molecular Encapsulation: Utilizing beta-cyclodextrins allows for the formation of inclusion complexes where the VHCl molecule is shielded within a hydrophobic cavity, effectively "hiding" the bitter moiety during oral transit.
- Resinate Formation: Ion-exchange resins (e.g., Kyron T-114) bind the drug in a stable complex at salivary pH, only releasing the active cation once it reaches the acidic environment of the stomach.

Advanced Manufacturing Processes

The evolution of ODT manufacturing has progressed from traditional methods to sophisticated engineering techniques that maximize internal surface area and porosity.

Sublimation and Microwave Irradiation

To create a highly porous matrix, volatile components (such as camphor or ammonium bicarbonate) are incorporated and subsequently removed. Goel et al. and Wongjumpoo et al. demonstrated that this "pore-forming" approach significantly reduces wetting time. Furthermore, Taopatom et al. innovated this further by using microwave-assisted sublimation, which achieves a record-breaking disintegration time of approximately 18 seconds by creating a uniform, interconnected pore network.

Innovative Approaches: 3D Printing and Solid Foams

- Additive Manufacturing: Li et al. have explored 3D printing (FDM or PAM) to customize VHCl dosage forms. This allows for precise control over the tablet's internal geometry, optimizing the surface-area-to-volume ratio for instantaneous melting.
- Solid Foam Technology: Hanczvikli et al. investigated the use of solid foams, which utilize air entrapment to create an ultra-lightweight matrix that liquefies immediately upon contact with minimal salivary volumes.[11-13]

Table 1:Technique and method of formulation

Technique	Primary Advantage	Typical Disintegration Time
Direct Compression	Cost-effective / Scalable	30–60 Seconds
Sublimation	High Porosity	20–40 Seconds
Microwave Sublimation	Ultra-rapid	< 20 Seconds
Lyophilization	Best "Melt" feel	< 10 Seconds

Evaluation Parameters and Quality Benchmarks

The characterization of Verapamil Hydrochloride (VHCl) ODTs requires specialized protocols that transcend standard pharmacopoeial tablet testing, focusing specifically on the kinetics of moisture interaction and mechanical resilience.

Wetting Kinetics and Water Uptake

Wetting time serves as the primary *in vitro* predictor for how a tablet will behave in the limited fluid environment of the human sublingual space.

- Methodology: Typically, a tablet is placed on a moisture-saturated tissue medium, and the duration required for complete surface hydration is recorded
- Influencing Factors: Markisio et al. Identified that the crystallinity of fillers like Mannitol significantly dictates the speed of water ingress. Furthermore, the Water Absorption Ratio is calculated to quantify the swelling capacity of the internal superdisintegrants, a metric essential for predicting matrix burst strength.

Disintegration and Texture Analysis

While the USP <701> apparatus provides a baseline, researchers now favor modified methods to simulate the oral cavity's low-volume environment (~2 mL of fluid).

- Rapid Response: Optimized formulations, particularly those utilizing microwave-assisted sublimation, have achieved total fragmentation in as little as 18–24 seconds.
- Mechanical Profiling: Narazaki et al introduced the use of Texture Analyzers to measure the "penetration distance" of moisture, providing a more granular look at how the tablet liquefies under simulated tongue pressure.

In Vitro Dissolution and Bioavailability Surrogates

For VHCl, the dissolution test must demonstrate a "burst release" to justify the ODT's clinical use for acute conditions.

- Release Profiles: Using USP Type II (Paddle) apparatus, studies by Sahoo et al. and Kabir et al. show that optimized ODTs can achieve >90% drug release within the first 10 minutes.
- Permeability Insights: Gwak et al. established that this rapid dissolution is a prerequisite for effective transmucosal absorption, directly impacting the eventual C {max} (peak plasma concentration) of the drug.

Clinical Perspectives and Future Outlook

The transition of Verapamil from a standard oral dose to an ODT format represents a significant leap in Patient-Centric Medicine.

Addressing Clinical Gaps

The primary clinical driver for VHCl-ODTs is the mitigation of the first-pass metabolic effect. By facilitating absorption through the highly vascularized buccal and sublingual mucosa, these systems allow the drug to bypass the hepatic CYP3A4 enzymes initially. This "metabolic bypass" not only improves absolute bioavailability

but also potentially reduces the inter-patient variability often seen with traditional Verapamil dosing.

Enhancing Compliance in Vulnerable Populations

For the pediatric and geriatric cohorts, the "melt-in-mouth" feature removes the physiological and psychological barriers associated with swallowing large pills (Dysphagia). Pradel et al. and Stegemann et al. emphasize that the ease of administration without water significantly improves adherence in long-term cardiovascular therapy[14-19]

Conclusion

The integration of high-performance superdisintegrants, sophisticated taste-masking complexes, and advanced manufacturing like 3D printing has transformed Verapamil into a versatile, rapid-response therapeutic tool. As pharmaceutical sciences move toward personalized dosing, VHCl-ODTs stand at the intersection of engineering precision and clinical necessity, offering a promising solution for the rapid management of hypertensive and arrhythmic episodes.

References

1. Chein YW. 2nd ed. New York: Marcel Dekker; 1992. Oral drug delivery and delivery systems.
2. Lindgren S, Janzon L. Dysphagia: Prevalence of swallowing complaints and clinical finding. Med Clin North Am. 1993;77:3–5.
3. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21:433–76.
4. Bandari S, Mittapalli RK, Gannu R, Rao YM. Orodispersible tablets: An overview. Asian J of Pham. 2008;2:2–11.
5. Habib W, Khankari RK, Hontz J. Fast dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17:61–7
6. Brown D. Orally disintegrating tablets-taste over speed. Drug Del Technol. 2003;3:58–61.
7. Seager H. Drug delivery products and Zydis fast-dissolving forms. J Pharm Pharmacol. 1998;50:375–82.
8. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H. Mitrazapine orally disintegrating tablet versus sertraline: A prospective onset of action study. J Clin Psychopharmacol. 2003;23:358–64.
9. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, et al. A new formulation of selegilline: Improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1241–55
10. Dobetti L. Fast-melting tablets: Developments and technologies. Pharm Technol N Am. 2001;12(9):4
11. Yang S, Fu Y, Jeong SH, Park K. Application of poly (acrylic acid) superporous hydrogel microparticles as super disintegrants in fast disintegrating tablets. J Pharm Pharmacol. 2004;56:429–36.
12. Ozeki T, Yasuzawa Y, Katsuyama H, Takshima Y, Kasai T, Eguchi T. Design of rapidly disintegrating oral tablets using acid-treated yeast cell wall: A technical note. AAPS Pharm Sci Tech. 2003;4:E70.
13. Radke RS, Jadhav JK, Chajeed MR. Formulation and evaluation of orodispersible tablets of baclofen. Int J Chem Tech Res. 2009;1:5
14. Swamy PV, Shahidulla SM, Shirsand SB, Hiremath SN, Ali MY. Orodispersible tablets of carbmszepine prepared by direct compression method using 32 full factorial designs. J Pharm Sci. 2008;7:1–5
15. Allen LV, Wang B. Process for making a particulate support matrix for making a rapidly dissolving dosage form. US Patent 6.207. 2001:199.
16. Allen LV, Wang B, Davis LD. Rapid dissolving tablet. US Patent6.807. 1998:576.
17. Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int J Pharm. 2004;278:423–33.
18. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release. 2005;105:16–22.
19. Satinder Kakar, Ramandeep Singh, Saurav Kumar. Orodispersible tablets: an overview . MOJ Proteomics & Bioinformatics. 2018;7(3):180-182

Conflict of Interest: Nil Source of support: None